Physician profile
Christopher Bifano
NPI 1003806910
$5,045.31
in general payments reported to CMS, 2019-2025
13 companies · $739 in 2025
The $739 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $520 · 2021: $646 · 2022: $939 · 2023: $659 · 2024: $929 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,304 · Entertainment: $22.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,304.47 |
| Entertainment | $22.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $3,282.20 | 2019-2025 | Clariti Contact Lens |
| Sight Sciences, INC. | $732.95 | 2022-2025 | Tearcare System |
| Biotissue Holdings INC. | $284.20 | 2024 | |
| Alcon Vision LLC | $263.59 | 2019-2025 | Precision7, Dailies Total1, Precision 1 |
| Lombart Brothers, INC. | $98.74 | 2022 | |
| Bausch & Lomb Americas INC. | $79.97 | 2023 | Infuse, Alden Scleral Zenlens |
| Optos, INC. | $68.35 | 2019-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Glaukos Corporation | $64.96 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $61.50 | 2019-2020 | |
| Carl Zeiss Meditec, INC. | $50.03 | 2020 | |
| Oyster Point Pharma, INC. | $29.14 | 2024 | Tyrvaya |
| Lkc Technologies, INC. | $16.38 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $13.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bifano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.